These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26026101)

  • 1. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.
    Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE
    Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
    Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
    Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
    Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
    Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
    Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
    Starbuck KD; Drake RD; Budd GT; Rose PG
    Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
    Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
    World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.
    Liu L; Dehner C; Grandhi N; Lyu Y; Borcherding DC; Chrisinger JSA; Zhang X; Luo J; Tao Y; Parkes A; Bui NQ; Davis EJ; Milhem MM; Monga V; Weiss M; Tine BV; Hirbe AC
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
    Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
    Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
    Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
    Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous perivascular epithelioid cell tumor: a clinicopathological and molecular reappraisal.
    Charli-Joseph Y; Saggini A; Vemula S; Weier J; Mirza S; LeBoit PE
    J Am Acad Dermatol; 2014 Dec; 71(6):1127-36. PubMed ID: 25267378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
    Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
    Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
    Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
    Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM
    J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
    Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH LITERATURE REVIEW.
    Damirov F; Menge F; Hohenberger P
    Georgian Med News; 2022 Nov; (332):56-59. PubMed ID: 36701777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics.
    Cohen PR; Kato SM; Erickson CP; Calame A; Kurzrock R
    Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant PEComa of the adrenal gland.
    Lau SK
    Pathol Res Pract; 2012 Feb; 208(2):113-7. PubMed ID: 22154607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features.
    Williamson SR; Bunde PJ; Montironi R; Lopez-Beltran A; Zhang S; Wang M; Maclennan GT; Cheng L
    Am J Surg Pathol; 2013 Oct; 37(10):1619-26. PubMed ID: 23797724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.